Chronic pain education: past, present, and future of psychedelics for the management of chronic pain

• by Christopher L Robinson, Pawan K Solanki, Sean Snyder, Adam Amir, Antje Barreveld, Rory Vu Mather, Ivo H Cerda, Michael Motoc, Harman Chopra, Robert Jason Yong, Joel Castellanos, Timothy Furnish, Alan D Kaye, Vwaire Orhurhu, Trent Emerick

• December 10, 2024

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

• by Kathryn Wighton

• May 27, 2026

• 5 min

Decentralized Trials Expand Access—but Risk Inequity

Remote clinical research is proliferating fast. The field is still working out who gets left behind.

• by Kerri Miller

• April 15, 2026

• 4 min

Is “Against Medical Advice” Still Defensible?

A Viewpoint calls for more dignifying, harm-reduction–oriented hospital discharges for patients with OUD.

• by Kerri Miller

• April 14, 2026

• 3 min